Landmark clinical trials that evaluated the role of SGLT-2 inhibitors in CKD required optimization of RAS blockade with either an ACE inhibitor or an ARB, reinforcing their adjunctive rather than substitutive role (22–24). The gene discussed is SLC5A2; the disease is chronic kidney disease.